作者: Scott A Tomlins , Daniel H Hovelson , Jennifer M Suga , Daniel M Anderson , Han A Koh
DOI: 10.1101/2020.11.19.20233866
关键词:
摘要: Abstract Purpose Tissue-based comprehensive genomic profiling (CGP) is increasingly utilized for treatment selection in patients with advanced solid tumors, however real-world tissue availability may limit widespread implementation. Here we established CGP and assessed performance on consecutively received samples. Patients Method Post-hoc, non-prespecified analysis of 32,048 consecutive tumor samples StrataNGS, a multiplex PCR based-CGP (PCR-CGP) test, as part an ongoing observational trial (NCT03061305). Tumor sample characteristics PCR-CGP were across all tested samples, including exception not meeting minimum input requirements ( 5yrs). Tests reporting at least one prioritized alteration or sequencing QC metrics (and ≥20% TC) considered successful. For prostate carcinoma lung adenocarcinoma, tests actionable/informative those actionable. Results was attempted 31,165 (97.2%) Among the 10.7% had low Conclusion Most from cancer desiring are limited, requiring optimized approaches to produce meaningful results. An coupled inclusive testing policy, delivered reportable results >94% potentially expanding proportion CGP-testable patients, thus impact biomarker-guided targeted immunotherapies.